• 1
    Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 2003; 21( suppl): 149s-167s.
  • 2
    Kavanagh H, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995; 13: 1584-1588.
  • 3
    Overmoyer B. Combination chemotherapy for metastatic breast cancer: reaching for the cure. J Clin Oncol. 2003; 21: 588-592.
  • 4
    Perez AT, Domenech GH, Frankel C, Vogel CL. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer. The Cancer Research Network, Inc, experience. Cancer Invest. 2002; 20( suppl 2): 22-29.
  • 5
    Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther. 2002; 2: 143-150.
  • 6
    Escobar PF, Markman M, Zanotti K, Webster K, Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol. 2003; 129: 651-654.
  • 7
    Colbern GT, Musterer R, Hiller AJ, et al. Treatment of palmar-plantar erythrodysesthesia syndrome (PPE) in patients receiving selected chemotherapeutic agents [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 409a.
  • 8
    Hussein MA, Wood L, Saluan MA, et al. Efficacy of pyridoxine to ameliorate cutaneous toxicity associated with Doxil [abstract]. Blood. 1998; 92( 10 suppl 1): 265b.
  • 9
    Patle JS. Pyridoxine for hand-foot syndrome. Hosp Pharm. 1999; 34: 604-609.
  • 10
    Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res. 1998; 4: 1567-1571.
  • 11
    Yee S, Safra T, Jeffers S, et al. Prevention and management of Doxil-related side effects: basic strategies [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 72a.
  • 12
    Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000; 89: 1037-1047.
  • 13
    Mangili G, Petrone M, Gentile C, DeMarzi P, Vigano R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008; 108: 332-335.
  • 14
    Molpus KL, Anderson LB, Craig CL, Puleo JG. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol. 2004; 93: 513-516.
  • 15
    Denda M, Inoue K, Fuziwara S, Denda S. P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption. J Invest Dermatol. 2002; 119: 1034-1040.
  • 16
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
  • 17
    von Gruenigen VE, Frasure HE, Grandon M, et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006; 103: 120-126.
  • 18
    von Gruenigen VE, Gil KM, Huang H, et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer. 2009; 115: 4857-4864.
  • 19
    The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. FACIT questionnaires. Available at Accessed June 7, 2009.
  • 20
    National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 3. Bethesda, Md: National Cancer Institute; 2006. Available at: Accessed August 9, 2006.
  • 21
    Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation [serial online]. Health Qual Life Outcomes. 2003; 1: 79.
  • 22
    Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001; 19: 1809-1817.
  • 23
    Gordon AN, Gleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
  • 24
    Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2005; 23: 5605-5612.
  • 25
    Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005; 28: 192-211.
  • 26
    Tanyi JL, Smith JA, Ramos L, et al. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol. 2009; 114: 219-224.
  • 27
    Cady FM, Kneuper-Hall R, Metcalf JS. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions. Am J Dermatopathol. 2006; 28: 168-172.
  • 28
    Mangana J, Zisper MC, Conrad C, et al. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol. 2008; 18: 566-570.
  • 29
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008; 144: 886-892.
  • 30
    Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15: 1411-1416.
  • 31
    Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008; 26: 3709-3714.
  • 32
    Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996; 63: 89-93.
  • 33
    Zhang MM, Chan JK, Husain A, Guo HY, Teng NN. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2007; 105: 194-198.
  • 34
    Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006; 102: 300-308.
  • 35
    Marquez CB, Smithberger EE, Bair SM, et al. Multiple keratoracanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009; 16: 66-69.
  • 36
    Chiara S, Nobile MT, Barzacchi C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer. 1997; 33: 967-969.
  • 37
    von Gruenigen VE, Huang HQ, Gil KM, et al. A comparison of quality of life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study. J Pain Symptom Manage. 2010; 39: 839-846.